证券代码：603882 证券简称：金域医学 公告编号：2025-038 广州金域医学检验集团股份有限公司 关于计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、计提资产减值准备情况概述 为了客观、公允地反映广州金域医学检验集团股份有限公司（以下简称"公 司"）2025 年半年度的财务状况以及经营成果，根据《企业会计准则》相关规 定和公司会计政策，公司对截至 2025 年 6 月 30 日的合并报表范围内各项资产进 行了减值测试，相应计提资产减值准备。详见下表： 单位：人民币元 二、计提资产减值准备的具体说明 （一）信用减值损失 | 类别 | 2025 年 1-6 月 | | --- | --- | | 一、信用减值损失 | 272,474,717.40 | | 其中：应收账款减值损失 | 271,491,843.98 | | 其他应收款信用减值损失 | 982,873.42 | | 二、资产减值损失 | -125,413.97 | | 其中：合同资产减值损失 | -125,413.97 | | 合计 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-037 广州金域医学检验集团股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 (一)股东会类型和届次 2025年第二次临时股东会 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 9 日 14 点 30 分 召开地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 9 月 9 日 至2025 年 9 月 9 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 股东会召开日期：2025年9月9日 本次股东会采用的网络投票系统：上海证券 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-035 广州金域医学检验集团股份有限公司 第四届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第四届监事会第 六次会议于 2025 年 8 月 22 日在公司会议室以现场的方式召开，会议通知已于 2025 年 8 月 12 日以电子形式发出。会议由监事会主席张栋先生主持，本次会议 应出席监事 3 名，实际出席监事 3 名。本次会议的通知和召开程序符合《中华人 民共和国公司法》、《广州金域医学检验集团股份有限公司章程》的相关规定，本 次会议及其决议合法有效。 二、监事会会议审议情况 经审议，监事会认为，2025 年半年度报告的编制和审议程序符合法律、法 规、公司章程和公司内部管理制度的各项规定；报告的内容和格式符合中国证监 会和上海证券交易所的各项规定，所包含的信息能真实、准确、完整地反映出公 司报告期内的经营管理和财务状况等事项；未发现参与报告编制和审议的人员有 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-034 广州金域医学检验集团股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第四届董事会第 七次会议于 2025 年 8 月 22 日在公司会议室以现场加通讯方式召开，会议通知已 于 2025 年 8 月 12 日以电子形式发出。会议由董事长梁耀铭先生主持，本次会议 应出席董事 9 名，实际出席董事 9 名。公司监事及高级管理人员列席本次会议。 会议召开符合《中华人民共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以记名投票 表决方式通过以下决议： （一）审议通过《广州金域医学检验集团股份有限公司 2025 年半年度报告 全文及摘要》 本议案经公司第四届董事会审计委员会 2025 年第三次会议审议通过，并同 意提交董事会审议。 经审议，董事会认为，公司依据相关法律、法规等 ...

[Definitions](index=5&type=section&id=Item%201.%20Definitions) This chapter defines key terms and abbreviations used in the report, covering company entities, medical and technical terminology, and business models, providing a foundation for understanding the report's content - The Company/Company/Joint Stock Company/Group/KingMed Diagnostics refers to Guangzhou KingMed Diagnostics Group Co., Ltd[13](index=13&type=chunk) - The report defines numerous subsidiaries and related entities, such as Guangzhou KingMed Diagnostics Center Co., Ltd., Guangzhou KingMed Judicial Expertise Technology Co., Ltd., and KingMed Hong Kong[13](index=13&type=chunk)[14](index=14&type=chunk) - The report also explains medical and technical terms, including medical laboratories, medical testing, ISO15189, CAP, AI, DRG, NGS, and CAR-T[15](index=15&type=chunk)[16](index=16&type=chunk)[17](index=17&type=chunk)[18](index=18&type=chunk) [Company Profile and Key Financial Indicators](index=10&type=section&id=Item%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) This chapter provides the company's basic information, contact details, stock overview, and key financial data and indicators for the first half of 2025, showing significant declines in revenue and net profit due to macroeconomic factors, policy adjustments, and increased credit impairment losses, with the company focusing on its core medical testing business, profit orientation, innovation, and digital transformation for high-quality development - The company's full name is Guangzhou KingMed Diagnostics Group Co., Ltd., with stock abbreviation KingMed Diagnostics and stock code 603882, listed on the Shanghai Stock Exchange[20](index=20&type=chunk)[24](index=24&type=chunk) Key Accounting Data for the First Half of 2025 | Item | Current Period (Jan-Jun) (CNY) | Prior Period (CNY) | Change from Prior Period (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 2,996,929,115.16 | 3,880,906,151.11 | -22.78 | | Total Profit | -109,608,128.07 | 96,877,336.59 | -213.14 | | Net Profit Attributable to Shareholders of Listed Company | -84,806,829.28 | 89,650,203.48 | -194.60 | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Gains and Losses) | -97,962,797.01 | 74,249,430.17 | -231.94 | | Net Cash Flow from Operating Activities | 350,469,491.45 | 34,282,611.46 | 922.30 | Key Financial Indicators for the First Half of 2025 | Key Financial Indicators | Current Period (Jan-Jun) | Prior Period | Change from Prior Period | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (CNY/share) | -0.18 | 0.19 | -194.74 | | Diluted Earnings Per Share (CNY/share) | -0.18 | 0.19 | -194.74 | | Basic Earnings Per Share (Excluding Non-Recurring Gains and Losses) (CNY/share) | -0.21 | 0.16 | -231.25 | | Weighted Average Return on Net Assets (%) | -1.21 | 1.08 | Decreased by 2.29 percentage points | | Weighted Average Return on Net Assets (Excluding Non-Recurring Gains and Losses) (%) | -1.40 | 0.90 | Decreased by 2.30 percentage points | - The main reasons for the performance decline are: 1) Short-term business development pressure due to economic cycles and industry macroeconomic policies, with the company actively optimizing customer structure, leading to lower-than-expected revenue and decreased operating leverage efficiency due to high fixed costs; 2) Extended collection cycles for some accounts receivable, resulting in a credit impairment loss of **CNY 272.47 million**[29](index=29&type=chunk) - The company will continue to focus on its core medical testing business, guided by profit, managing cash flow and quality revenue, and building core capabilities around five strategic initiatives: marketing model upgrades, product portfolio strategy, differentiated services, cost leadership, and digital transformation[29](index=29&type=chunk) - Total non-recurring gains and losses for the reporting period amounted to **CNY 13.16 million**, primarily including disposal gains/losses on non-current assets, government subsidies, and other non-operating income and expenses[31](index=31&type=chunk) [Management Discussion and Analysis](index=14&type=section&id=Item%203.%20Management%20Discussion%20and%20Analysis) This chapter delves into the industry's macroeconomic changes, the company's main business operations, operating strategies and achievements during the reporting period, and core competitive advantages, as the company actively responds to challenges and opportunities from deepening medical reform and the explosion of AI technology, consolidating market position and improving operational efficiency through product innovation, regional service integration, cost control, and digital transformation [Explanation of the Company's Industry and Main Business Operations During the Reporting Period](index=14&type=section&id=I.%20Explanation%20of%20the%20Company's%20Industry%20and%20Main%20Business%20Operations%20During%20the%20Reporting%20Period) During the reporting period, the medical testing industry entered a period of deep adjustment driven by deepening medical reform, AI technology development, integrated medical care system construction, and data element application, with the company, as a third-party medical testing and pathology diagnosis service provider, actively adapting to market changes through technological innovation and network coverage to provide internationally standardized medical diagnostic information integration services - Medical reform continues to deepen, with DRG/DIP 2.0 grouping schemes implemented nationwide and medical testing item prices reduced in many regions, leading to a short-term shift from incremental competition to a coexistence of incremental and existing competition, putting pressure on industry players to contract performance and improve quality and efficiency[33](index=33&type=chunk) - In the long run, medical institutions' demand for outsourced medical testing services may increase due to cost-benefit considerations, potentially boosting industry penetration and solidifying the competitive position of leading enterprises[34](index=34&type=chunk) - The explosive development of artificial intelligence technology, represented by generative AI, is driving deeper applications in the medical field, such as AI warning agents improving pathology report review efficiency by **300%**, and AI medical agents providing intelligent report interpretation services[34](index=34&type=chunk) - The advancement of integrated county-level medical care system construction is shifting customer demand from single-point services to regional overall operational services, requiring market participants to expand core capabilities across multiple domains[35](index=35&type=chunk) - The 'data element x' effect is deepening, with national and local policies accelerating implementation, promoting the datafication and marketization of medical data, and the industry is moving from data resource construction to a new stage of data asset operation and value mining[36](index=36&type=chunk) - The company's main business is third-party medical testing and pathology diagnosis, offering over **4,200 testing items** across **11 major categories** and over **90 types** of medical testing and testing+AI technologies, having established **50 medical laboratories** in mainland China, Hong Kong, and Macau, with a service network covering over **90% of the national population**[36](index=36&type=chunk) - The company continues to deepen its 'Medical Testing 4.0' strategy, leveraging the 'Yujian Yiyan' large model and 'Xiaoyu Yi' intelligent agent applications to accelerate the deep integration of AI and data elements in clinical research, technological innovation, and other fields, building a smart medical testing ecosystem[37](index=37&type=chunk) [Discussion and Analysis of Operations](index=16&type=section&id=II.%20Discussion%20and%20Analysis%20of%20Operations) During the reporting period, the company actively responded to external environmental fluctuations, adhering to its 'high-quality development, innovation-driven development, and group-wide integration' strategy, accelerating the implementation of its cost leadership strategy and unlocking data element value through optimizing product portfolios, developing regional testing and pathology center solutions, promoting standardized, intensive, and intelligent management, and continuously strengthening innovation capabilities - The company adheres to a clinical and disease-oriented approach, optimizing its product portfolio and continuously launching suitable products, such as upgrading the oncology 'Huimin 3000' product, reducing the minimum detection limit of the Huimin version MRD to **0.005%**, offering comprehensive solutions in the infection field, the 'Jin Xue Hui' series for hematological oncology, and three plasma markers for Alzheimer's disease in the neurological field[40](index=40&type=chunk)[41](index=41&type=chunk) - The company pioneered the 'intensive sharing + specialized services + digital empowerment' integrated medical care system solution, which has been implemented in multiple county-level integrated medical care projects, effectively reducing regional testing costs and increasing patient visit rates[42](index=42&type=chunk) - The cost leadership strategy is continuously advanced through standardization (KMSS service management platform, 'four unifications' in technology), intensification ('dry-wet separation management + centralized dispatch' production model, special testing platform integration, centralized production of long-tail projects), and intelligence (flow cytometry KMFLOW system, molecular pathology KMTR system, blood electrophoresis intelligent agent)[43](index=43&type=chunk)[44](index=44&type=chunk) - Innovation capabilities are continuously strengthened through participation in national major science and technology projects, publication of **42 papers**, acquisition of **147 new effective intellectual property rights** (**26 invention patents**), and industry-university-research collaborations with top-tier tertiary hospitals, such as establishing a joint laboratory with Children's Hospital of Fudan University[44](index=44&type=chunk)[45](index=45&type=chunk) - The company actively responded to the national call for data element value, achieving significant results in business digitalization (supply chain, KMSS, HR systems, smart laboratory early warning intelligent agents improving efficiency), digital business (**21 data products** listed on data exchanges, over **20 collaborations** with pharmaceutical companies, 'Xiaoyu Yi' monthly active doctors exceeding **60,000**), and digital infrastructure (data governance, cloud-native AI computing hybrid cloud platform reducing costs by over **30%**)[46](index=46&type=chunk)[47](index=47&type=chunk) [Analysis of Core Competitiveness During the Reporting Period](index=17&type=section&id=III.%20Analysis%20of%20Core%20Competitiveness%20During%20the%20Reporting%20Period) The company has built a solid core competitive advantage, supporting its sustainable development, through an internationally leading quality management system, clinical and disease-oriented product technology advantages, extensive service network, industry-leading digital transformation capabilities, a three-chain integrated scientific innovation ecosystem, and a high-caliber talent team - A 'grand quality' ecosystem has been established, with over **180 international certification certificates** including CNAS and CAP, enabling testing reports to be recognized in over **80 countries and regions worldwide**, leading the industry for **23 consecutive years**[49](index=49&type=chunk) - Possessing over **90 types** of internationally advanced medical testing and testing+AI technology platforms, a comprehensive testing product system covering the 'full life cycle, full disease spectrum, and full diagnostic process' for clinical needs has been established, launching cost-effective 'Huimin' product series, providing nearly **3 million testing services** cumulatively[50](index=50&type=chunk) - Fifty medical laboratories have been established in mainland China, Hong Kong, and Macau, supported by over **2,400 self-built logistics outlets**, with a service network covering over **90% of the national population**, and a full-chain digital cold chain service capability has been built[51](index=51&type=chunk) - Comprehensive digital transformation is underway, creating a 'medical testing industry large model + intelligent agent' paradigm, pioneering a pathology early warning system, accumulating over **3 billion medical testing data records**, being the first to achieve data product listing, on-exchange trading, and asset capitalization, and building a cloud-native AI computing hybrid cloud platform[52](index=52&type=chunk)[53](index=53&type=chunk) - Guided by the integration of innovation, industry, and value chains, a 'Medical Testing+' innovation ecosystem has been built, leading and participating in the formulation and revision of **102 standards** (**67 published**), and undertaking a national-level pilot project for standardized cold chain logistics services for biological samples[54](index=54&type=chunk) - A high-quality talent pipeline has been systematically built, led by industry experts, supported by multi-level technical backbones, and driven by innovative composite talents, deepening the '721' training model and launching a series of training programs such as the 'Digital Intelligence Lecture Hall'[55](index=55&type=chunk)[56](index=56&type=chunk) [Key Operating Performance During the Reporting Period](index=20&type=section&id=IV.%20Key%20Operating%20Performance%20During%20the%20Reporting%20Period) This chapter analyzes the company's financial statement item changes, asset and liability situation, investment status, and operating performance of major subsidiaries during the reporting period, showing a year-on-year decrease in operating revenue and total profit, but a significant increase in net cash flow from operating activities, with adjustments to the asset and liability structure, where overseas assets account for 6.07%, and continued investment in private equity funds and subsidiaries, with some subsidiaries incurring losses Analysis of Changes in Financial Statement Items | Item | Current Period (CNY) | Prior Period (CNY) | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 2,996,929,115.16 | 3,880,906,151.11 | -22.78 | | Operating Cost | 1,979,982,984.96 | 2,531,982,051.80 | -21.80 | | Selling Expenses | 420,766,367.51 | 453,413,287.27 | -7.20 | | Administrative Expenses | 285,478,221.51 | 316,142,511.94 | -9.70 | | Financial Expenses | -2,727,820.44 | 133,865.79 | -2,137.73 | | R&D Expenses | 160,713,609.90 | 196,771,885.67 | -18.32 | | Net Cash Flow from Operating Activities | 350,469,491.45 | 34,282,611.46 | 922.30 | - The change in financial expenses was primarily due to a decrease in interest expenses; the significant increase in net cash flow from operating activities was mainly due to strengthened collection management and cost control, leading to reduced operating expenditures[58](index=58&type=chunk) Changes in Assets and Liabilities | Item | Current Period End (CNY) | Change from Prior Year End (%) | Explanation | | :--- | :--- | :--- | :--- | | Contract Assets | 20,427,003.08 | -37.80 | Primarily due to a corresponding decrease with changes in operating scale | | Other Current Assets | 107,561,319.53 | -35.20 | Primarily due to a decrease in prepaid income tax | | Development Expenditures | 5,093,805.62 | 51.85 | Primarily due to increased investment in data resource development | | Other Non-Current Assets | 9,392,486.44 | 55.44 | Primarily due to an increase in prepayments for constructing long-term assets | | Taxes Payable | 39,415,825.12 | -45.75 | Primarily due to a decrease in income tax payable | | Non-Current Liabilities Due Within One Year | 153,781,381.86 | 34.81 | Primarily due to an increase in long-term borrowings due within one year | - Overseas assets amounted to **CNY 594.15 million**, accounting for **6.07%** of total assets[63](index=63&type=chunk) Major Asset Restrictions as of the End of the Reporting Period | Item | Book Value at Period End (CNY) | Reason for Restriction | | :--- | :--- | :--- | | Cash and Bank Balances | 11,780,897.52 | Deposits and funds frozen due to litigation | | Intangible Assets | 10,768,960.64 | Pledged for borrowings | | Construction in Progress | 60,445,003.01 | Pledged for borrowings | | Total | 82,994,861.17 | | - As of the end of the reporting period, the company's consolidated financial statements showed a balance of **CNY 174.80 million** in long-term equity investments, an increase of **CNY 0.28 million** from the end of the previous year; the balance of other non-current financial assets was **CNY 283.35 million**, an increase of **CNY 32.83 million** from the end of the previous year[65](index=65&type=chunk) Private Equity Fund Investments | Private Equity Fund Name | Company's Shareholding in Private Equity Fund (%) | Amount Invested as of Period End (CNY) | | :--- | :--- | :--- | | Guangzhou Jinyuan Investment Management Partnership (Limited Partnership) | 10.00 | 19,334,208.48 | | Beijing Huagai Xincheng Yuanhang Medical Industry Investment Partnership (Limited Partnership) | 1.65 | 44,404,642.93 | | Cathay Global Healthcare Fund | 3.30 | 19,146,409.55 | | Wanwu Phase I (Xiamen) Venture Capital Partnership (Limited Partnership) | 4.32 | 31,157,229.00 | Net Profit of Major Subsidiaries | Company Name | Operating Revenue (CNY 10,000) | Net Profit (CNY 10,000) | | :--- | :--- | :--- | | Guangzhou KingMed Diagnostics Center Co., Ltd. | 85,831.48 | 4,145.33 | | Changsha KingMed Diagnostics Laboratory Co., Ltd. | 20,651.90 | 1,464.92 | | Kunming KingMed Diagnostics Institute Co., Ltd. | 21,636.80 | 1,430.29 | | Gansu KingMed Diagnostics Institute Co., Ltd. | 4,260.43 | -1,706.11 | | Guangxi KingMed Diagnostics Laboratory Co., Ltd. | 7,685.83 | -1,829.66 | | Zhengzhou KingMed Clinical Laboratory Co., Ltd. | 20,586.36 | -4,107.43 | | Xi'an KingMed Diagnostics Institute Co., Ltd. | 9,717.49 | -4,569.42 | [Other Disclosures](index=26&type=section&id=V.%20Other%20Disclosures) This chapter discloses the significant risks the company may face, including policy, market, quality, technology, supply chain, and funding risks, and details the measures taken to implement the 'Quality Improvement, Efficiency Enhancement, and Return Focus' action plan, such as comprehensively improving operational quality, deepening market value management, and enhancing information disclosure quality to boost investor confidence - The company faces policy risks, as deepening medical reform, DRG/DIP payment method reforms, and medical service price adjustments may lead to downward pressure on medical testing item prices, intensifying industry competition and affecting short-term performance[70](index=70&type=chunk) - The company faces market risks, with changing demand from medical institutions for outsourced testing services, requiring industry players to rapidly innovate, improve operational efficiency, and explore new growth points[70](index=70&type=chunk) - The company faces quality risks, with significant challenges in pre-analytical quality control of samples, potentially leading to accidental errors in test results, triggering medical disputes, and damaging market reputation[70](index=70&type=chunk) - The company faces technological risks, as AI diagnostic capabilities become a core competitive advantage, and deviations in technology application from clinical value or insufficient R&D capabilities may impact continuous operations[71](index=71&type=chunk) - The company faces supply chain risks, as international uncertainties may lead to increased supply and costs of upstream equipment, reagents, and key raw materials[71](index=71&type=chunk) - The company faces funding risks, as collections for some businesses fall short of expectations, and large amounts of accounts receivable with extended aging periods may lead to cash flow pressure and impact profits[71](index=71&type=chunk) - The company implemented the 'Quality Improvement, Efficiency Enhancement, and Return Focus' action plan, achieving a **21% year-on-year increase** in laboratory per capita efficiency in 2024, strengthening cost advantages through intensive production, optimized logistics routes (logistics costs decreased by **7.29% year-on-year**), and integrated supply chain management (reagent costs decreased by **15.54% year-on-year**)[72](index=72&type=chunk)[73](index=73&type=chunk)[74](index=74&type=chunk) - Multi-disciplinary digital intelligence scenarios have been implemented, such as the cervical cancer smart screening workstation improving per capita efficiency by **4 times**, the high-flexibility flow cytometry pre-processing workstation saving labor upon commissioning, and electrophoresis AI and mycoplasma intelligent identification AI enhancing diagnostic efficiency[75](index=75&type=chunk) - Market value management has been deepened, with **CNY 209.98 million** in share repurchases implemented in 2024, and the purpose of **5,513,000 repurchased shares** changed to cancellation; cash dividends of **CNY 407.67 million** were distributed in the first three quarters of 2024[76](index=76&type=chunk) - Information disclosure quality has been improved, with the release of 'KingMed Diagnostics Periodic Report in One Picture' series articles and English versions of reports, and communication with investors through various channels such as the 'SSE e-interaction' platform, investor hotlines, and performance briefings[77](index=77&type=chunk)[78](index=78&type=chunk) [Corporate Governance, Environment, and Society](index=29&type=section&id=Item%204.%20Corporate%20Governance%2C%20Environment%2C%20and%20Society) This chapter covers the company's governance structure, changes in the board of directors and management (none during the reporting period), profit distribution plan (none for the half-year), progress of equity incentive plans, and the company's practices in environmental and social responsibility, particularly its contributions to rural revitalization and various public welfare activities, demonstrating its social commitment - During the reporting period, there were no changes in the company's board of directors, supervisory board, or senior management[80](index=80&type=chunk) - There was no proposed profit distribution plan or capital reserve to share capital increase plan for the half-year period[80](index=80&type=chunk) - The company's 2020 and 2021 stock option incentive plans are in progress, with some granted but unexercised stock options cancelled, but no new developments or changes occurred during the reporting period[81](index=81&type=chunk)[82](index=82&type=chunk) - The company continues to contribute to rural revitalization, collaboratively establishing **150 medical laboratories** in **122 poverty-stricken counties** across **17 provinces, cities, and autonomous regions**, with a cumulative investment of **CNY 4.37 million** in construction funds, enhancing grassroots medical testing service capabilities[84](index=84&type=chunk) - In collaboration with Guangzhou KingMed Public Welfare Foundation, the company carried out a series of public welfare activities such as 'Five Cancer Early Screening Health Escort,' ''Rare' Guard Extraordinary' rare disease public welfare activities, and 'Love Liver Action,' providing health assistance to vulnerable and special populations[84](index=84&type=chunk) [Significant Matters](index=32&type=section&id=Item%205.%20Significant%20Matters) This chapter details the company's and its related parties' commitments during or continuing into the reporting period, including resolving horizontal competition, regulating related-party transactions, share lock-ups, and measures to mitigate the dilution of immediate returns, while confirming no non-operating fund occupation by controlling shareholders, illegal guarantees, or major litigation/arbitration, and disclosing daily related-party transactions - The company's controlling shareholder and actual controller, Liang Yaoming, and his concerted parties, committed to long-term resolution of horizontal competition, not directly or indirectly engaging in competitive business activities identical or similar to the company's main business[86](index=86&type=chunk)[87](index=87&type=chunk)[92](index=92&type=chunk)[93](index=93&type=chunk) - The company's controlling shareholder, actual controller and their concerted parties, shareholders holding more than 5% of the company's shares, and the company's non-independent directors, supervisors, and senior management committed to long-term resolution of related-party transactions, adhering to principles of equality, voluntariness, equivalence, and compensation to ensure fair pricing of related-party transactions[88](index=88&type=chunk) - Liang Yaoming committed that the newly issued shares acquired in this subscription shall not be transferred within **36 months** from the end of this non-public offering[88](index=88&type=chunk) - All company directors, senior management, and the controlling shareholder and actual controller, Liang Yaoming, committed to implementing compensatory measures to address the dilution of immediate returns from this offering, including not transferring benefits without compensation or under unfair conditions, restricting job-related consumption, and not using company assets for unrelated investments[89](index=89&type=chunk)[90](index=90&type=chunk) - The company has formulated a stock price stabilization plan, which will sequentially initiate measures such as company share repurchases, increased holdings by the actual controller and their concerted parties, and increased holdings by directors and senior management, when the stock's closing price falls below the audited net asset value per share of the previous fiscal year for **20 consecutive trading days**[94](index=94&type=chunk)[95](index=95&type=chunk)[96](index=96&type=chunk)[97](index=97&type=chunk)[98](index=98&type=chunk) - The company's actual controller and their concerted parties committed to unconditionally bearing all related back payments and penalties if the company or its subsidiaries are found to have violated any social security laws and regulations[91](index=91&type=chunk) - During the reporting period, there was no non-operating occupation of funds by controlling shareholders or other related parties, nor were there any instances of providing external guarantees in violation of prescribed decision-making procedures[99](index=99&type=chunk) - There were no significant litigation or arbitration matters during the reporting period[100](index=100&type=chunk) Related-Party Transactions for Purchase and Sale of Goods/Acceptance of Services | Related Party | Related Transaction Content | Current Period Amount (CNY) | Approved Transaction Limit (CNY) | | :--- | :--- | :--- | :--- | | Jinqirui | Purchase of Goods | 138,066,917.78 | 205,000,000.00 | | Jinmanli | Purchase of Goods | 17,038,106.82 | 132,500,000.00 | | KingMed Future | Purchase of Goods | 7,824.78 | Not applicable | Related-Party Transactions for Sale of Goods/Provision of Services | Related Party | Related Transaction Content | Current Period Amount (CNY) | | :--- | :--- | :--- | | Jinqirui | Logistics Services | 347,198.73 | | Jinqirui | Sale of Goods | 36,066.77 | | KingMed Public Welfare Foundation | Testing Services | 13,789.00 | | Jinmanli | Testing Services | 36,088,792.21 | | Jinmanli | Sale of Goods | 1,561,505.91 | Related-Party Lease Income (as Lessor) | Lessee Name | Type of Leased Asset | Lease Income Recognized in Current Period (CNY) | | :--- | :--- | :--- | | KingMed Future | Rent and Management Fees | 236,118.71 | | KingMed Public Welfare Foundation | Rent and Management Fees | 62,474.70 | - Key management personnel compensation for the current period amounted to **CNY 4.66 million**[186](index=186&type=chunk) - From January to June 2025, the company donated a total of **CNY 0.18 million** to Guangzhou KingMed Public Welfare Foundation[186](index=186&type=chunk) Accounts Receivable from Related Parties | Item | Related Party | Book Balance at Period End (CNY) | Provision for Bad Debts (CNY) | | :--- | :--- | :--- | :--- | | Accounts Receivable | Jinqirui | 1,171,423.32 | 11,714.23 | | Accounts Receivable | KingMed Public Welfare Foundation | 28,372.30 | 283.72 | | Accounts Receivable | Jinmanli | 20,017,563.00 | 200,175.63 | Accounts Payable to Related Parties | Item | Related Party | Book Balance at Period End (CNY) | | :--- | :--- | :--- | | Accounts Payable | Jinqirui | 180,367,765.90 | | Accounts Payable | Jinmanli | 18,060,393.23 | [Share Changes and Shareholder Information](index=46&type=section&id=Item%206.%20Share%20Changes%20and%20Shareholder%20Information) This chapter discloses that the company's total share capital and share structure remained unchanged during the reporting period, and details the total number of shareholders, the top ten shareholders' holdings and their related relationships, and changes in restricted shares as of the end of the reporting period - During the reporting period, there were no changes in the company's total share capital or share structure[106](index=106&type=chunk) - As of the end of the reporting period, the total number of common shareholders was **42,347**[107](index=107&type=chunk) Top Ten Shareholders' Shareholdings as of the End of the Reporting Period | Shareholder Name | Number of Shares Held at Period End (shares) | Proportion (%) | Number of Restricted Shares Held (shares) | Share Status | Quantity (shares) | Shareholder Nature | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Liang Yaoming | 74,191,907 | 16.02 | 3,123,698 | Pledged | 23,000,000 | Domestic Natural Person | | Hong Kong Securities Clearing Company Limited | 38,373,277 | 8.28 | 0 | Unknown | 0 | Other | | Guochuang Kaiyuan Equity Investment Fund (Limited Partnership) | 30,880,905 | 6.67 | 0 | Unknown | 0 | Other | | Guangzhou Xinmanyu Investment Consulting Partnership (Limited Partnership) | 28,590,102 | 6.17 | 0 | None | 0 | Other | | Guangzhou Shengyufang Investment Consulting Partnership (Limited Partnership) | 21,000,000 | 4.53 | 0 | Pledged | 8,580,000 | Other | | Guangzhou Shengboyu Investment Consulting Partnership (Limited Partnership) | 19,298,752 | 4.17 | 0 | None | 0 | Other | | Guangzhou Ruizhi Investment Consulting Partnership (Limited Partnership) | 14,902,860 | 3.22 | 0 | None | 0 | Other | | Bank of China Co., Ltd. - Hwabao CSI Medical ETF | 9,130,115 | 1.97 | 0 | Unknown | 0 | Other | | Bank of China Co., Ltd. - China Merchants Advantage Enterprise Flexible Allocation Mixed Securities Investment Fund | 6,499,959 | 1.40 | 0 | Unknown | 0 | Other | | Ruizhong Life Insurance Co., Ltd. - Proprietary Funds | 5,775,797 | 1.25 | 0 | Unknown | 0 | Other | - Among the company's top ten shareholders, the actual controller and controlling shareholder, Liang Yaoming, holds **7.12%**, **10.03%**, **99%**, and **9.96%** stakes in Guangzhou Xinmanyu Investment Consulting Partnership (Limited Partnership), Guangzhou Shengboyu Investment Consulting Partnership (Limited Partnership), Guangzhou Shengyufang Investment Consulting Partnership (Limited Partnership), and Guangzhou Ruizhi Investment Consulting Partnership (Limited Partnership), respectively, and serves as the general partner for these four entities[113](index=113&type=chunk) Number of Shares Held by Top Ten Restricted Shareholders and Restriction Conditions | No. | Name of Restricted Shareholder | Number of Restricted Shares Held (shares) | Restriction Conditions | | :--- | :--- | :--- | :--- | | 1 | Liang Yaoming | 3,123,698 | Restricted for 36 months from the listing date | [Bond-Related Information](index=51&type=section&id=Item%207.%20Bond-Related%20Information) This chapter clarifies that the company had no corporate bonds (including enterprise bonds) or non-financial enterprise debt financing instruments, nor any convertible corporate bonds during the reporting period - The company has no corporate bonds (including enterprise bonds) or non-financial enterprise debt financing instruments[119](index=119&type=chunk) - The company has no convertible corporate bonds[119](index=119&type=chunk) [Financial Report](index=52&type=section&id=Item%208.%20Financial%20Report) This chapter presents the company's unaudited consolidated and parent company financial statements for the first half of 2025, including the balance sheet, income statement, cash flow statement, and statement of changes in owners' equity, accompanied by detailed financial statement notes covering the company's basic information, accounting policies, taxes, specific financial item details, R&D expenditures, changes in consolidation scope, equity in other entities, government grants, financial instrument risks, fair value disclosures, related parties and related-party transactions, share-based payments, commitments and contingencies, post-balance sheet events, and supplementary information [Audit Report](index=52&type=section&id=I.%20Audit%20Report) This chapter states that the company's 2025 semi-annual report is unaudited - This semi-annual report is unaudited[5](index=5&type=chunk) [Financial Statements](index=52&type=section&id=II.%20Financial%20Statements) This chapter presents the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity for the first half of 2025, comprehensively reflecting the company's financial position, operating results, and cash flows at the end of the reporting period Consolidated Balance Sheet (June 30, 2025) | Item | June 30, 2025 (CNY) | December 31, 2024 (CNY) | | :--- | :--- | :--- | | Total Current Assets | 6,704,565,580.68 | 7,318,237,550.29 | | Total Non-Current Assets | 3,078,939,700.78 | 3,073,656,192.20 | | Total Assets | 9,783,505,281.46 | 10,391,893,742.49 | | Total Current Liabilities | 2,172,694,707.23 | 2,232,415,119.56 | | Total Non-Current Liabilities | 662,745,089.81 | 684,406,029.88 | | Total Liabilities | 2,835,439,797.04 | 2,916,821,149.44 | | Total Equity Attributable to Parent Company Owners | 6,824,524,149.74 | 7,325,269,947.15 | | Non-Controlling Interests | 123,541,334.68 | 149,802,645.90 | | Total Owners' Equity | 6,948,065,484.42 | 7,475,072,593.05 | Consolidated Income Statement (Jan-Jun 2025) | Item | First Half of 2025 (CNY) | First Half of 2024 (CNY) | | :--- | :--- | :--- | | Total Operating Revenue | 2,996,929,115.16 | 3,880,906,151.11 | | Total Operating Costs | 2,850,900,501.38 | 3,506,295,279.47 | | Operating Profit | -106,098,268.05 | 102,101,217.33 | | Total Profit | -109,608,128.07 | 96,877,336.59 | | Net Profit | -96,868,140.52 | 83,261,928.89 | | Net Profit Attributable to Parent Company Shareholders | -84,806,829.28 | 89,650,203.48 | | Non-Controlling Interests' Share of Profit or Loss | -12,061,311.24 | -6,388,274.59 | Consolidated Cash Flow Statement (Jan-Jun 2025) | Item | First Half of 2025 (CNY) | First Half of 2024 (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 350,469,491.45 | 34,282,611.46 | | Net Cash Flow from Investing Activities | -199,327,528.97 | -212,102,171.70 | | Net Cash Flow from Financing Activities | -401,358,881.88 | -484,345,131.63 | | Net Increase in Cash and Cash Equivalents | -257,245,342.13 | -659,127,283.89 | | Cash and Cash Equivalents at Period End | 2,165,279,207.49 | 1,790,546,857.34 | [Company Basic Information](index=74&type=section&id=III.%20Company%20Basic%20Information) This chapter outlines the establishment background, listing information, registered capital, main business, and actual controller of Guangzhou KingMed Diagnostics Group Co., Ltd., providing essential context for understanding the company's financial statements - The company's full name is Guangzhou KingMed Diagnostics Group Co., Ltd., listed on the Shanghai Stock Exchange in September 2017[154](index=154&type=chunk) - As of June 30, 2025, the company's total accumulated issued share capital and registered capital both amounted to **CNY 463.26 million**[154](index=154&type=chunk) - The company's main business activity is medical diagnostic services, and its actual controller is Liang Yaoming[154](index=154&type=chunk) [Basis of Financial Statement Preparation](index=74&type=section&id=IV.%20Basis%20of%20Financial%20Statement%20Preparation) This chapter states that the company's financial statements are prepared in accordance with the Accounting Standards for Business Enterprises issued by the Ministry of Finance and relevant regulations of the China Securities Regulatory Commission, and on a going concern basis - The financial statements are prepared in accordance with the 'Accounting Standards for Business Enterprises' issued by the Ministry of Finance and 'No. 15 Rules for Information Disclosure by Companies Issuing Securities to the Public - General Provisions on Financial Reports' issued by the China Securities Regulatory Commission[155](index=155&type=chunk) - These financial statements are prepared on a going concern basis[156](index=156&type=chunk) [Significant Accounting Policies and Estimates](index=74&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This chapter details the significant accounting policies and estimates adopted by the company in preparing its financial statements, covering key areas such as financial instrument classification and measurement, inventory valuation, long-term equity investments, depreciation of fixed assets, amortization of intangible assets, revenue recognition, government grants, deferred income tax, and leases, providing the basis for understanding the accounting treatment behind the financial data - Financial assets are classified based on business models and contractual cash flow characteristics into those measured at amortized cost, at fair value through other comprehensive income, and at fair value through profit or loss[174](index=174&type=chunk) - Inventories are classified as raw materials, merchandise inventory, goods in transit, etc., initially measured at cost, valued using the weighted average method upon issuance, and measured at the lower of cost or net realizable value at the balance sheet date[188](index=188&type=chunk)[190](index=190&type=chunk) - Long-term equity investments in subsidiaries are accounted for using the cost method, while long-term equity investments in associates and joint ventures are accounted for using the equity method[198](index=198&type=chunk) Depreciation Methods for Fixed Assets | Category | Depreciation Method | Depreciation Period (Years) | Salvage Rate | Annual Depreciation Rate | | :--- | :--- | :--- | :--- | :--- | | Buildings | Straight-line method | 30 | 5 | 3.17 | | Specialized Equipment | Straight-line method | 5 | 0-5 | 19.00-20.00 | | Transportation Equipment | Straight-line method | 5 | 0-5 | 19.00-20.00 | | General Equipment | Straight-line method | 3, 5 | 0-5 | 19.00-33.33 | | Fixed Asset Improvements | Straight-line method | 5 | 0 | 20.00 | - Intangible assets (such as software, proprietary technology, data resources) are amortized using the straight-line method, with finite-lived intangible assets amortized over the period they are expected to bring economic benefits to the enterprise, and indefinite-lived intangible assets not amortized[213](index=213&type=chunk)[217](index=217&type=chunk) - Revenue recognition processes include medical diagnostic services, reagent sales, health check-up services, logistics services, and health consulting services, all recognized when performance obligations are satisfied and payment is expected to be recoverable[227](index=227&type=chunk)[228](index=228&type=chunk) - Government grants are classified as asset-related or income-related, recognized when conditions are met and received, and accounted for as deferred income or current profit or loss based on their nature[230](index=230&type=chunk)[233](index=233&type=chunk)[234](index=234&type=chunk) - As a lessee, for leases other than short-term leases and low-value asset leases, right-of-use assets and lease liabilities are recognized, with depreciation calculated using the straight-line method and interest expenses recognized[238](index=238&type=chunk)[239](index=239&type=chunk) [Taxes](index=94&type=section&id=VI.%20Taxes) This chapter details the main tax categories, tax bases, and applicable tax rates for the company and its subsidiaries, and discloses various tax preferential policies, including high-tech enterprise income tax incentives, Western Development Strategy incentives, and inclusive tax reductions for small and micro enterprises, which positively impact the company's tax burden Major Tax Categories and Rates | Tax Category | Tax Base | Tax Rate | | :--- | :--- | :--- | | Value-Added Tax (VAT) | Based on sales of goods and taxable services calculated according to tax laws, output VAT is determined, and after deducting input VAT allowed for the current period, the difference is VAT payable | 13% (reagent sales), 6% (medical services, technical services, auxiliary logistics services), 5% (real estate leasing acquired before April 30, 2016) | | Urban Maintenance and Construction Tax | Calculated based on actual VAT and consumption tax paid | 7% | | Enterprise Income Tax | Calculated based on taxable income | 25%, 15%, 20%, 17%, 16.5% | - Several subsidiaries (e.g., Guangzhou KingMed Diagnostics, Jinan KingMed Diagnostics) qualify as high-tech enterprises and are eligible for a reduced enterprise income tax rate of **15%**[248](index=248&type=chunk)[249](index=249&type=chunk)[250](index=250&type=chunk)[251](index=251&type=chunk)[252](index=252&type=chunk)[253](index=253&type=chunk)[254](index=254&type=chunk)[255](index=255&type=chunk)[256](index=256&type=chunk)[257](index=257&type=chunk)[258](index=258&type=chunk) - Some subsidiaries (e.g., Xi'an KingMed Diagnostics, Gansu KingMed Diagnostics, Xinjiang KingMed Diagnostics) benefit from tax policies related to the Western Development Strategy, allowing them to pay enterprise income tax at a reduced rate of **15%**[249](index=249&type=chunk)[255](index=255&type=chunk)[256](index=256&type=chunk)[257](index=257&type=chunk)[259](index=259&type=chunk) - Subsidiaries such as Guangzhou KingMed Judicial Expertise Technology Co., Ltd. and Guangzhou Jinzhi Testing Technology Co., Ltd. pay enterprise income tax at a rate of **20%** in accordance with the 'Notice on Implementing Inclusive Tax Reduction Policies for Small and Micro Enterprises' issued by the Ministry of Finance and the State Taxation Administration[245](index=245&type=chunk)[260](index=260&type=chunk) - Medical services provided by medical institutions are exempt from Value-Added Tax, and international freight forwarding services are also exempt from Value-Added Tax[247](index=247&type=chunk) - The loss carry-forward period for high-tech enterprises and technology-based small and medium-sized enterprises has been extended from **5 years to 10 years**[260](index=260&type=chunk) - From January 1, 2023, to December 31, 2027, VAT small-scale taxpayers, small low-profit enterprises, and individual industrial and commercial households may be eligible for a **50% reduction** in resource tax, urban maintenance and construction tax, property tax, and other taxes within the specified tax amount range[261](index=261&type=chunk) [Notes to Consolidated Financial Statement Items](index=100&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This chapter provides detailed notes for each item in the consolidated financial statements, including cash and bank balances, accounts receivable, contract assets, inventories, long-term equity investments, fixed assets, construction in progress, intangible assets, goodwill, deferred income tax, short-term borrowings, accounts payable, contract liabilities, employee benefits payable, long-term borrowings, deferred income, operating revenue and costs, credit impairment losses, investment income, and cash flows, explaining the period-end balances, changes, and accounting treatments for each item - The period-end cash and bank balances amounted to **CNY 2.18 billion**, of which **CNY 511.06 million** was deposited overseas[263](index=263&type=chunk) - The period-end book balance of accounts receivable was **CNY 5.87 billion**, with a bad debt provision of **CNY 1.76 billion**, representing a provision rate of **30.02%**[272](index=272&type=chunk)[275](index=275&type=chunk) - The period-end book value of contract assets was **CNY 20.43 million**, with a bad debt provision of **CNY 0.21 million**, representing a provision rate of **1.00%**[281](index=281&type=chunk)[285](index=285&type=chunk) - The period-end inventory balance was **CNY 190.72 million**, primarily composed of raw materials (**CNY 167.84 million**) and merchandise inventory (**CNY 14.94 million**)[307](index=307&type=chunk)[308](index=308&type=chunk) - The period-end balance of other non-current financial assets was **CNY 283.35 million**, measured at fair value with changes recognized in current profit or loss[319](index=319&type=chunk) - The period-end book value of fixed assets was **CNY 1.13 billion**[326](index=326&type=chunk) - The period-end balance of construction in progress was **CNY 629.00 million**, with major projects including Suzhou KingMed Construction Project (**CNY 252.35 million**) and KingMed Group Innovation Center Project (**CNY 131.70 million**)[330](index=330&type=chunk) - The period-end book value of intangible assets was **CNY 163.63 million**, of which data resources accounted for **CNY 3.27 million**[340](index=340&type=chunk)[342](index=342&type=chunk) - The original book value of goodwill was **CNY 52.21 million**, primarily arising from the acquisitions of Saier Medical Testing and Tianhai Xinyu[344](index=344&type=chunk) - The period-end balance of deferred income tax assets was **CNY 287.07 million**, mainly from asset impairment provisions and deductible losses[349](index=349&type=chunk) - The period-end balance of short-term borrowings was **CNY 0**, a significant decrease from **CNY 1.00 million** at the beginning of the period[362](index=362&type=chunk) - The period-end balance of accounts payable was **CNY 1.69 billion**, primarily for supplier settlements[364](index=364&type=chunk) - The period-end balance of contract liabilities was **CNY 63.44 million**, primarily for unbilled amounts received from customers[367](index=367&type=chunk) - The period-end balance of employee benefits payable was **CNY 130.73 million**[369](index=369&type=chunk) - The period-end balance of long-term borrowings was **CNY 509.03 million**, including secured and unsecured borrowings[382](index=382&type=chunk) - The period-end balance of deferred income was **CNY 18.70 million**, primarily from government grants[386](index=386&type=chunk) Operating Revenue and Operating Cost by Contract Type (Jan-Jun 2025) | Contract Type | Operating Revenue (CNY) | Operating Cost (CNY) | | :--- | :--- | :--- | | Medical Diagnostic Services | 2,732,240,241.04 | 1,822,792,026.26 | | Sales of Diagnostic Products | 193,118,902.01 | 109,011,817.78 | | Health Check-up Services | 8,042,109.03 | 6,795,779.72 | | Cold Chain Logistics Services | 18,593,238.01 | 14,280,610.13 | | Other | 44,013,220.03 | 26,555,097.51 | | **Total** | **2,996,007,710.12** | **1,979,435,331.41** | - Credit impairment losses for the current period amounted to **CNY -272.47 million**, primarily from bad debt losses on accounts receivable[412](index=412&type=chunk) - Investment income for the current period amounted to **CNY 2.01 million**, primarily including income from long-term equity investments accounted for using the equity method and investment income from other non-current financial assets held during the period[409](index=409&type=chunk)[411](index=411&type=chunk) - The net increase in cash and cash equivalents was **CNY -257.25 million**, with a period-end balance of **CNY 2.17 billion**[427](index=427&type=chunk) [R&D Expenditures](index=165&type=section&id=VIII.%20R%26D%20Expenditures) This chapter details the company's R&D expenditures during the reporting period, including expensed and capitalized R&D expenditures, categorized by nature of expense, reflecting the company's investment in research and development R&D Expenditures by Nature of Expense | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Salaries and Wages | 85,067,536.53 | 94,564,914.59 | | Material Costs | 54,148,226.67 | 69,358,463.65 | | Depreciation Expenses | 17,705,298.18 | 18,607,327.40 | | Other | 5,531,945.71 | 14,241,180.03 | | Total | 162,453,007.09 | 196,771,885.67 | | Of which: Expensed R&D Expenditures | 160,713,609.90 | 196,771,885.67 | | Capitalized R&D Expenditures | 1,739,397.19 | 0 | - Current period capitalized R&D expenditures were primarily for data resource development, with a period-end balance of **CNY 5.09 million**[437](index=437&type=chunk) [Changes in Consolidation Scope](index=166&type=section&id=IX.%20Changes%20in%20Consolidation%20Scope) This chapter explains the changes in the company's consolidation scope during the reporting period, primarily due to the subsidiary KingMed Diagnostics (Hong Kong) Co., Ltd. investing in and establishing Kingwik Pte. Ltd., which was subsequently included in the consolidation scope - In May 2025, the subsidiary KingMed Diagnostics (Hong Kong) Co., Ltd. invested in and established Kingwik Pte. Ltd., which has been included in the consolidation scope since May 2025[438](index=438&type=chunk) [Equity in Other Entities](index=168&type=section&id=X.%20Equity%20in%20Other%20Entities) This chapter details the company's equity interests in subsidiaries, joint ventures, and associates, including their basic information, shareholding percentages, business nature, and key financial information for significant non-wholly owned subsidiaries, as well as financial data for important joint ventures and associates - The company owns numerous subsidiaries primarily engaged in medical diagnostic services, located across various provinces and cities in mainland China, Hong Kong, and Macau, with most shareholdings at **100%**[440](index=440&type=chunk)[441](index=441&type=chunk)[442](index=442&type=chunk)[443](index=443&type=chunk) Financial Information of Significant Non-Wholly Owned Subsidiaries | Subsidiary Name | Non-Controlling Interest Shareholding (%) | Profit or Loss Attributable to Non-Controlling Interests in Current Period (CNY) | Dividends Declared to Non-Controlling Interests in Current Period (CNY) | Non-Controlling Interests Balance at Period End (CNY) | | :--- | :--- | :--- | :--- | :--- | | Guangzhou KingMed Diagnostics | 15 | 7,151,789.61 | 0 | 52,906,476.33 | | Xi'an KingMed Diagnostics | 38 | -17,363,809.02 | 13,300,000 | 69,546,021.58 | - The company's significant joint venture is DRA COMPANY LIMITED, with a **50%** shareholding and business nature of R&D[449](index=449&type=chunk) Key Financial Information of Significant Joint Venture DRA COMPANY LIMITED | Item | Period-End Balance/Current Period Amount (CNY) | Beginning Balance/Prior Period Amount (CNY) | | :--- | :--- | :--- | | Total Assets | 37,978,850.32 | 47,047,965.97 | | Total Liabilities | 40,007.25 | 194,427.65 | | Equity Attributable to Parent Company Shareholders | 37,938,843.07 | 46,853,538.31 | | Net Profit | -8,914,695.24 | -8,386,582.75 | Summary Financial Information of Insignificant Associates | Item | Period-End Balance/Current Period Amount (CNY) | | :--- | :--- | | Total Book Value of Investments | 154,509,012.51 | | Net Profit | 4,453,628.21 | | Total Comprehensive Income | 4,453,628.21 | [Government Grants](index=177&type=section&id=XI.%20Government%20Grants) This chapter discloses the government grants received by the company during the reporting period, including the balance of government grants recognized as deferred income and the amount of government grants recognized in current profit or loss, distinguishing between asset-related and income-related grants Liability Items Involving Government Grants | Financial Statement Item | Beginning Balance (CNY) | New Grants Added in Current Period (CNY) | Transferred to Other Income in Current Period (CNY) | Period-End Balance (CNY) | Asset-Related/Income-Related | | :--- | :--- | :--- | :--- | :--- | :--- | | Deferred Income | 22,379,444.34 | 145,000.00 | 3,825,286.59 | 18,699,157.75 | Asset-Related/Income-Related | Government Grants Recognized in Current Profit or Loss | Type | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Asset-Related | 2,300,514.36 | 2,463,502.72 | | Income-Related | 13,471,637.83 | 18,951,887.97 | | Total | 15,772,152.19 | 21,415,390.69 | [Risks Related to Financial Instruments](index=177&type=section&id=XII.%20Risks%20Related%20to%20Financial%20Instruments) This chapter describes the credit risk, liquidity risk, and market risk (including foreign exchange risk, interest rate risk, and other price risks) faced by the company in its operations, and details the policies and measures taken to identify, assess, and manage these risks to ensure financial stability - The company faces credit risk, liquidity risk, and market risk (including foreign exchange risk, interest rate risk, and other price risks)[457](index=457&type=chunk) - Credit risk primarily arises from cash and bank balances, accounts receivable, contract assets, other receivables, etc., and is managed by depositing funds in reputable banks and regularly monitoring customer creditworthiness[458](index=458&type=chunk) - Liquidity risk is managed by ensuring sufficient cash, monitoring cash balances, readily marketable securities, and rolling forecasts of cash flows for the next **12 months**[459](index=459&type=chunk) - Market risk includes interest rate risk (managed by balancing the proportion of fixed and floating rate financial instruments), foreign exchange risk (mitigated by monitoring foreign currency transactions and asset-liability scale), and other price risks (primarily from equity instrument investments)[459](index=459&type=chunk)[460](index=460&type=chunk)[461](index=461&type=chunk)[462](index=462&type=chunk) [Fair Value Disclosures](index=179&type=section&id=XIII.%20Fair%20Value%20Disclosures) This chapter discloses the fair values of the company's assets and liabilities measured at fair value at the end of the reporting period, categorized by fair value measurement hierarchy, primarily involving Level 3 fair value measurements for other non-current financial assets Fair Value of Assets and Liabilities Measured at Fair Value at Period End | Item | Level 3 Fair Value Measurement (CNY) | Total (CNY) | | :--- | :--- | :--- | | I. Recurring Fair Value Measurements | | | | (I) Financial Assets at Fair Value Through Profit or Loss | 283,350,518.25 | 283,350,518.25 | | 2. Financial assets designated at fair value through profit or loss | 283,350,518.25 | 283,350,518.25 | | Total assets measured at recurring fair value | 283,350,518.25 | 283,350,518.25 | - Fair value measurement hierarchy is divided into Level 1 (unadjusted quoted prices in active markets), Level 2 (observable inputs other than Level 1), and Level 3 (unobservable inputs)[467](index=467&type=chunk)[468](index=468&type=chunk)[469](index=469&type=chunk) [Related Parties and Related-Party Transactions](index=182&type=section&id=XIV.%20Related%20Parties%20and%20Related-Party%20Transactions) This chapter identifies the company's parent company, subsidiaries, joint ventures, associates, and other related parties, and discloses various related-party transactions during the reporting period, including purchases and sales of goods, provision and acceptance of services, related-party leases, key management personnel compensation, and accounts receivable and payable with related parties - The company's ultimate controlling party is Liang Yaoming, who directly holds **16.02%** of the company's equity and collectively possesses **34.10%** of the voting rights through controlling other partnerships[182](index=182&type=chunk) - Other related parties include Guangzhou Jiajian Biotechnology Co., Ltd. and its subsidiary Guangzhou Jinqirui Biotechnology Co., Ltd., significantly influenced by Liang Yaoming; Guangdong KingMed Future Biotechnology Co., Ltd., a subsidiary of a joint venture; and Guangzhou KingMed Public Welfare Foundation, significantly influenced by key management personnel[182](index=182&type=chunk)[183](index=183&type=chunk) Related-Party Transactions for Purchase and Sale of Goods/Acceptance of Services | Related Party | Related Transaction Content | Current Period Amount (CNY) | Approved Transaction Limit (CNY) | | :--- | :--- | :--- | :--- | | Jinqirui | Purchase of Goods | 138,066,917.78 | 205,000,000.00 | | Jinmanli | Purchase of Goods | 17,038,106.82 | 132,500,000.00 | | KingMed Future | Purchase of Goods | 7,824.78 | Not applicable | Related-Party Transactions for Sale of Goods/Provision of Services | Related Party | Related Transaction Content | Current Period Amount (CNY) | | :--- | :--- | :--- | | Jinqirui | Logistics Services | 347,198.73 | | Jinqirui | Sale of Goods | 36,066.77 | | KingMed Public Welfare Foundation | Testing Services | 13,789.00 | | Jinmanli | Testing Services | 36,088,792.21 | | Jinmanli | Sale of Goods | 1,561,505.91 | Related-Party Lease Income (as Lessor) | Lessee Name | Type of Leased Asset | Lease Income Recognized in Current Period (CNY) | | :--- | :--- | :--- | | KingMed Future | Rent and Management Fees | 236,118.71 | | KingMed Public Welfare Foundation | Rent and Management Fees | 62,474.70 | - Key management personnel compensation for the current period amounted to **CNY 4.66 million**[186](index=186&type=chunk) - The company donated a total of **CNY 0.18 million** to Guangzhou KingMed Public Welfare Foundation in the current period[186](index=186&type=chunk) Accounts Receivable from Related Parties | Item | Related Party | Book Balance at Period End (CNY) | | :--- | :--- | :--- | | Accounts Receivable | Jinqirui | 1,171,423.32 | | Accounts Receivable | KingMed Public Welfare Foundation | 28,372.30 | | Accounts Receivable | Jinmanli | 20,017,563.00 | Accounts Payable to Related Parties | Item | Related Party | Book Balance at Period End (CNY) | | :--- | :--- | :--- | | Accounts Payable | Jinqirui | 180,367,765.90 | | Accounts Payable | Jinmanli | 18,060,393.23 | [Share-Based Payments](index=187&type=section&id=XV.%20Share-Based%20Payments) This chapter discloses the company's equity-settled share-based payment arrangements, including the method for determining the fair value of equity instruments at the grant date and the cumulative amount recognized in capital reserve, reflecting the company's employee incentive implementation - The cumulative amount of equity-settled share-based payments recognized in capital reserve was **CNY 223.32 million**[489](index=489&type=chunk) - The fair value of equity instruments at the grant date is determined through valuation and estimated based on the employment status of incentive recipients[489](index=489&type=chunk) [Commitments and Contingencies](index=188&type=section&id=XVI.%20Commitments%20and%20Contingencies) This chapter discloses the company's significant commitments as of the balance sheet date, primarily bank guarantees, and confirms the absence of any major contingent matters requiring disclosure Bank Guarantees Issued by the Company Pledged in CNY as of June 30, 2025 | Pledgee | Pledged Amount (CNY) | Amount of Guarantee Issued (CNY) | | :--- | :--- | :--- | | China Merchants Bank Shenzhen Cuizhu Sub-branch | 8,071,632.90 | 8,071,632.90 | | Bank of Tianjin Wanhua Sub-branch | 2,545.03 | Note | | China Construction Bank Suzhou Xiangcheng Sub-branch | 703,900.00 | 703,900.00 | | Total | 8,778,077.93 | 8,775,532.90 | - The company has no significant contingent matters requiring disclosure[491](index=491&type=chunk) [Post-Balance Sheet Events](index=188&type=section&id=XVII.%20Post-Balance%20Sheet%20Events) This chapter confirms that no significant non-adjusting events, profit distribution, or sales returns occurred between the balance sheet date and the report disclosure date - No significant non-adjusting events occurred after the balance sheet date[492](index=492&type=chunk) - No profit distribution occurred after the balance sheet date[492](index=492&type=chunk) - No sales returns occurred after the balance sheet date[492](index=492&type=chunk) [Other Significant Matters](index=189&type=section&id=XVIII.%20Other%20Significant%20Matters) This chapter confirms the absence of prior period accounting error corrections, significant debt restructurings, asset replacements, annuity plans, and discontinued operations, and states that the company has no reportable segments - The company has no prior period accounting error corrections, significant debt restructurings, asset replacements, annuity plans, or discontinued operations[192](index=192&type=chunk) - The company has no reportable segments[192](index=192&type=chunk) [Notes to Parent Company Financial Statement Items](index=190&type=section&id=XIX.%20Notes%20to%20Parent%20Company%20Financial%20Statement%20Items) This chapter provides detailed notes for key items in the parent company's financial statements, including other receivables, long-term equity investments, operating revenue and costs, and investment income, offering specific financial data and changes at the parent company level - The parent company's period-end balance of other receivables was **CNY 4.41 billion**, including **CNY 1.06 billion** in dividends receivable from subsidiaries and **CNY 3.35 billion** in other receivables (primarily intercompany balances and deposits)[495](index=495&type=chunk)[497](index=497&type=chunk)[502](index=502&type=chunk) - The parent company's period-end book value of long-term equity investments was **CNY 1.07 billion**, comprising investments in subsidiaries of **CNY 972.98 million** and investments in associates and joint ventures of **CNY 96.51 million**[510](index=510&type=chunk) - The parent company's other business income for the current period amounted to **CNY 11.02 million**, with operating costs of **CNY 5.02 million**[517](index=517&type=chunk) - The parent company's investment income for the current period amounted to **CNY 176.61 million**, primarily from long-term equity investment income accounted for using the cost method (**CNY 174.61 million**) and investment income from other non-current financial assets held during the period (**CNY 1.73 million**)[521](index=521&type=chunk) [Supplementary Information](index=203&type=section&id=XX.%20Supplementary%20Information) This chapter provides supplementary financial report information, including a detailed statement of non-recurring gains and losses, and calculations of return on net assets and earnings per share, offering investors more comprehensive financial analysis data Details of Non-Recurring Gains and Losses for the Current Period | Item | Amount (CNY) | | :--- | :--- | | Gains or losses on disposal of non-current assets, including the reversal of asset impairment provisions already made | 2,002,442.23 | | Government grants recognized in current profit or loss, excluding those closely related to the company's ordinary business activities, compliant with national policies, enjoyed according to fixed standards, and having a continuous impact on the company's profit or loss | 15,772,152.19 | | Other non-operating income and expenses apart from the above items | -3,070,341.11 | | Other profit or loss items that meet the definition of non-recurring gains and losses | 1,725,775.88 | | Less: Income tax impact | 2,100,938.18 | | Impact on non-controlling interests (after tax) | 1,173,123.28 | | Total | 13,155,967.73 | Return on Net Assets and Earnings Per Share | Profit for the Reporting Period | Weighted Average Return on Net Assets (%) | Basic Earnings Per Share (CNY/share) | Diluted Earnings Per Share (CNY/share) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Ordinary Shareholders of the Company | -1.21 | -0.18 | -0.18 | | Net Profit Attributable to Ordinary Shareholders of the Company (Excluding Non-Recurring Gains and Losses) | -1.40 | -0.21 | -0.21 |

广州金域医学检验集团股份有限公司 总经理工作细则 广州金域医学检验集团股份有限公司 总经理工作细则 第一章 总则 第一条 为提高广州金域医学检验集团股份有限公司（以下简称"公司"） 管理效率和科学管理水平，完善公司法人治理结构，明确总经理的职责，保障总 经理行使职权，促进公司稳定健康发展，根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上海证券交易所股票上市规则》等相关法律、法规和规范性文件及《广州金域 医学检验集团股份有限公司章程》（以下简称"《公司章程》"）的规定，特制 定本细则。 第二条 公司总经理由董事会聘任或解聘，总经理主持公司的经营管理工 作，组织实施董事会决议，对董事会负责。 本细则所称公司高级管理人员，包括公司总经理以及由董事会聘任的副总经 理、董事会秘书、财务总监等。 第三条 制订本细则的目的，在于明确总经理及公司其他高级管理人员的职 责权限，规范公司其他高级管理人员的经营管理行为和决策程序，促使公司经营 管理工作正常和有效进行，提高公司管理效率和科学决策水平。 第二章 任职资格 第四条 总经理和其他高级管理人员的基本任职条件 ...

广州金域医学检验集团股份有限公司 关联交易管理制度 广州金域医学检验集团股份有限公司 关联交易管理制度 第一章 总 则 第一条 为规范广州金域医学检验集团股份有限公司（以下简称"公司"）关 联交易行为，提高公司规范运作水平，保护投资者特别是中小投资者的合法权益， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上海证券交易所股票上市规则》（以下简称"《上 市规则》"）、《公开发行证券的公司信息披露内容与格式准则第 2 号——年度报告 的内容与格式》、《上海证券交易所上市公司自律监管指引第 5 号——交易与关联 交易》等有关法律、法规和规范性文件，以及《广州金域医学检验集团股份有限 公司章程》（以下简称"公司章程"）的有关规定，制定本规则。 第二条 公司交易与关联交易行为应当合法合规，不得隐瞒关联关系，不得 通过将关联交易非关联化规避相关审议程序和信息披露义务。相关交易不得存在 导致或者可能导致公司出现被控股股东、实际控制人及其他关联人非经营性资金 占用、为关联人违规提供担保或者其他被关联人侵占利益的情形。 第四条 公司临时报告和定期报告中非财务报 ...

广州金域医学检验集团股份有限公司 对外投资管理制度 广州金域医学检验集团股份有限公司 对外投资管理制度 第一章 总则 第一条 为规范广州金域医学检验集团股份有限公司（以下简称"公司"）的对外投 资行为，加强公司对外投资管理，防范对外投资风险，保障对外投资安全，提高对外 投资效益，维护公司形象和投资者的利益，依照《中华人民共和国公司法》（以下简 称"《公司法》"）、《上海证券交易所股票上市规则》（以下简称"《上市规则》"） 等相关法律、法规、规范性文件的规定，以及《广州金域医学检验集团股份有限公司 章程》（以下简称"《公司章程》"），结合公司的实际情况，制定本制度。 第二条 本制度所称的对外投资是指公司及公司为获取未来收益而将一定数量的货币 资金、股权、以及经评估后的实物或无形资产作价出资，对外进行各种形式的投资活 动。 第三条 按照投资期限的长短，公司对外投资分为短期投资和长期投资。短期投资主 要指公司购入的能随时变现且持有时间不超过一年（含一年）的投资，包括各种股票、 债券、基金、分红型保险等； 长期投资主要指投资期限超过一年，不能随时变现或不准备变现的各种投资，包 括债券投资、股权投资和其他投资等。包括但 ...

广州金域医学检验集团股份有限公司 章 程 二○二五年八月 | . | . | | --- | --- | | | - | | | œ 2 | | | | 广州金域医学检验集团股份有限公司 章程 第一章 总 则 第一条 为维护广州金域医学检验集团股份有限公司（下称"公司"）、股东、 职工和债权人的合法权益，规范公司的组织和行为，弘扬企业家精神，根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《上市公司章程指引》和其他有关规定，制订本章程。 第二条 公司系依照《公司法》有关规定成立的股份有限公司。 公司系由广州市金域投资咨询有限公司整体变更，并由全体发起人采取发起设立 方式设立的股份有限公司。公司在广州市市场监督管理局注册登记，取得《营业执照》， 统一社会信用代码为 9144010178891443XK。 第三条 公司于 2017 年 8 月 18 日经中国证券监督管理委员会批准，首次向社会 公众发行人民币普通股 6,868 万股，于 2017 年 9 月 8 日在上海证券交易所上市。 第四条 公司注册名称： 中文名称：广州金域医学检验集团股份有限公 ...

广州金域医学检验集团股份有限公司 内幕信息知情人管理制度 广州金域医学检验集团股份有限公司 内幕信息知情人管理制度 第一章 总 则 第一条 为规范广州金域医学检验集团股份有限公司（以下简称"公司"）内 幕信息管理，加强内幕信息保密工作，避免内幕交易，维护信息披露的公平原则， 保护广大投资者的合法权益，根据《中华人民共和国公司法》（以下简称"公司 法"）、 《中华人民共和国证券法》（以下简称"证券法"）、《上海证券交易 所股票上市规则》、《上市公司监管指引第 5 号－－上市公司内幕信息知情人登记 管理制度》等有关法律、法规和 《广州金域医学检验集团股份有限公司章程》 （以下简称"《公司章程》"）、《广州金域医学检验集团股份有限公司信息披露 管理办法》的有关规定，制定本制度。 第二条 本制度的适用范围包括公司及其下属各部门、子公司（包括公司直接 或间接持股 50%以上的子公司和其他纳入公司合并财务报表的子公司）以及公司能 够对其实施重大影响的参股公司（以下简称"参股公司"）。 第三条 公司董事会负责公司内幕信息知情人的登记管理工作，董事会秘书组 织实施；公司其他部门、子公司及公司能够对其实施重大影响的参股公司的负 ...